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Abstract Activation of the b-adrenergic receptor (bAR)
pathway is the main mechanism of the heart to increase
cardiac output via protein kinase A (PKA)-mediated
phosphorylation of cellular target proteins, and perturba-
tions therein may contribute to cardiac dysfunction in heart
failure. In the present study a comprehensive analysis was
made of mediators of the bAR pathway, myofilament
properties and cardiac structure in patients with idiopathic
(IDCM; n = 13) and ischemic (ISHD; n = 10) cardio-
myopathy in comparison to non-failing hearts (donor;
n = 10) for the following parameters: bAR density,
G-coupled receptor kinases 2 and 5, stimulatory and
inhibitory G-proteins, phosphorylation of myofilament
targets of PKA, protein phosphatase 1, phospholamban,
SERCA2a and single myocyte contractility. All parameters
exhibited the expected alterations of heart failure, but for
most of them the extent of alteration was greater in IDCM
than in ISHD. Histological analysis also revealed higher
collagen in IDCM compared to ISHD. Alterations in the
bAR pathway are more pronounced in IDCM than in ISHD
and may reflect sequential changes in cellular protein
composition and function. Our data indicate that cellular
dysfunction is more severe in IDCM than in ISHD.
Keywords b-Adrenergic receptor  Protein
phosphorylation  Myofilament function  Cardiomyocyte 
Collagen
Introduction
During increased cardiac stress stimulation of the
b-adrenergic receptors (bAR) exerts a positive inotropic
and lusitropic effect on the heart, via activation of protein
kinase A (PKA)-mediated phosphorylation of Ca2?-han-
dling and contractile proteins (Bers 2002; Brodde and
Michel. 1999; Kranias et al. 1985; Kentish et al. 2001;
Zhang et al. 1995). The positive inotropic effect largely
originates from increased cytosolic [Ca2?] during the sys-
tolic phase of the cardiac cycle. The positive lusitropic
effect results from increased cytosolic Ca2? re-uptake into
the sarcoplasmic reticulum, increased Ca2? removal out of
the cardiomyocyte, and desensitization of the myofilaments
for Ca2?. In patients with heart failure (HF) the sympa-
thetic nervous system is chronically activated to maintain
perfusion of vital organs via peripheral vasoconstriction
and via an increase in heart rate and in myocardial con-
tractility. Although aimed at maintaining cardiac pump
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function, chronic neurohumoral stimulation is detrimental
for cardiac function and results in uncoupling and down-
regulation of mediators of the bAR pathway (Brodde and
Michel 1999; Packer 1995). Abnormalities in this pathway
have been implicated as important determinants of dimin-
ished function of the failing human heart. The adverse
effects of neurohumoral overstimulation is illustrated by
the negative correlation between noradrenaline plasma
levels and prognosis of the patients (Cohn et al. 1984), and
by the improvement of symptoms and prolonged survival
of patients treated with b-blockers (Bohm and Maack
2000). In line with reduced b-adrenergic signaling,
previous studies in end-stage HF patients with idiopathic
cardiomyopathy showed reduced PKA-mediated phos-
phorylation of downstream myofilament target proteins,
cardiac myosin binding protein C (cMyBP-C) and troponin
I (cTnI) (El-Armouche et al. 2007; van der Velden et al.
2003; Messer et al. 2007, 2009; Copeland et al. 2010),
which coincided with increased myofilament Ca2?-sensi-
tivity (pCa50). In patients with diastolic heart failure (i.e.,
HF with preserved ejection fraction, HFPEF) hypo-
phosphorylation of titin has been associated with increased
cardiomyocyte stiffness (Fpassive) (Borbe´ly et al. 2009).
Insight in the modifications of the b-adrenergic pathway
and coincident changes in cardiomyocyte function is nee-
ded to develop targeted therapy in HF patients. In a recent
study we reported diverse changes at the myocardial
ultrastructural level with prominent cardiomyocyte hyper-
trophy in HFPEF patients and low myofibrillar density in
HF patients with reduced EF (HFREF) (van Heerebeek
et al. 2006). Moreover, Fpassive was higher in HFPEF than
in HFREF. These cellular differences may alter respon-
siveness to current HF treatment, which includes b-blocker
therapy. Likewise, patients with idiopathic (IDCM) and
ischemic (ISHD) cardiomyopathy may show diverse
cellular changes.
Although many studies investigated mediators of the
bAR signaling pathway and sarcomeric function in human
heart failure, a direct comparative investigation of both in
samples from IDCM and ISHD patients is lacking. Within
the present study a systematic analysis was performed from
the bAR to sarcomeric protein composition and function in
IDCM and ISHD patients, and compared to non-failing
donor myocardium (donor). Radioligand binding studies
were performed to determine bAR density. Protein analysis
included down-stream components of the adrenergic sig-
nalling cascade, the phospho-proteome of the myofila-
ments, and SERCA2a and phospholamban levels.
Myofilament function was determined in permeabilized
single cardiomyocytes. Histological analysis included car-
diomyocyte diameter, collagen volume fraction and myo-
fibrillar density.
Methods
Human ventricular tissue
Left ventricular (LV) tissue samples were obtained during
heart transplantation surgery from end-stage HF patients
(NYHA III-IV) with IDCM (n = 13; 10 males, 3 females;
mean age 51 ± 2 years) or ISHD (n = 10; 7 males, 3
females; mean age 51 ± 2 years)(Table 1). Patients were
classified to idiopathic dilated cardiomyopathy when the
heart showed LV dilatation and LV systolic dysfunction
with no identifiable cause and in the absence of coronary
artery disease, hypertension, valvular disease and congen-
ital heart disease sufficient to cause the observed myocar-
dial abnormality (Elliott et al. 2008). In contrast, patients
with ischemic heart disease had a history of myocardial
infarction and explanted hearts showed severe coronary
artery disease upon pathologic inspection. Medication
included angiotension-converting-enzyme inhibitors, angio-
tensin II receptor antagonists, diuretics, b-blockers, digoxin
and anti-arrhythmic agents and did not differ between the
IDCM and ISHD group. Tissue from 10 donor hearts
(Table 1; 8 males, 2 females; mean age 38 ± 6 years) served
as reference for non-failing myocardium. The tissue was
collected in cardioplegic solution and stored in liquid
nitrogen. Samples were obtained after informed consent and
with approval of the local Ethical Committee (St Vincents’
Hospital Human Research Ethics Committee, Sydney,
Australia: File number: H03/118; Title: Molecular Analysis
of Human Heart Failure). The investigation conforms
with the principles outlined in the Declaration of Helsinki
(1997).
Protein analysis
Radioligand binding
Tissue samples (~200 mg wet weight) were thawed in ice-
cold 1 mM KHCO3 solution, minced with scissors and then
homogenized with an Ultra-Turrax (Janke & Kunkel,
Staufen, Germany) for 10 s at maximum speed followed by
twice 20 s at 2/3 of maximum speed. The homogenates
were centrifuged for 15 min at 2509g and 4C. The
supernatant was filtered through medical gauze and cen-
trifuged for 20 min at 50,0009g at 4C. The sediment was
resuspended in binding buffer (10 mM Tris, 154 mM
NaCl, pH 7.4). Protein content was measured by the
method of Bradford using bovine IgG as standard.
Radioligand binding was performed as described earlier
(Niclauss et al. 2006) using a 90 min incubation at 37C
with [125I]iodocyanopindolol (ICYP; specific activity
2200 Ci/mmol, Perkin Elmer, Zaventem, Belgium) in a
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total volume of 250 ll. Non-specific binding was defined
as binding in the presence of 100 lM isoproterenol
(Sigma-Aldrich). All experiments were performed in
duplicates in 96 well plates, and incubations were termi-
nated by rapid vacuum filtration over Whatman GF/C using
a Filtermate harvester (Perkin Elmer). Each filter was
washed with approximately 10 ml of buffer. Radioactivity
adherent to the filters was quantified in a Topcount NXT
(Perkin Elmer) using Microsint O scintillator (Perkin
Elmer). To determine the relative amount of b1AR and
b2AR, membranes were incubated with ICYP (100 pM) in
the presence or absence of eight concentrations (range
10-10 to 10-3 M) of the highly selective b1AR antagonist
CGP 20712A (1-[2-((3-carbamoyl-4-hydroxy) phenoxy)
ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)
phenoxy]-2-propanol methanesulfonate).
Components of the b-adrenergic receptor pathway
Protein expression levels of G-coupled receptor kinases
(GRK2 and GRK5), G-proteins (Gs and Gi) and protein
phosphatase 1 (PP-1) were analyzed by one-dimensional
15% SDS-polyacrylamide gel electrophoresis (1D-PAGE)
and subsequent Western blotting. Samples were applied in
Table 1 Patient/heart characteristics
Sex Age cMyBP-C-P ProQ cTnI-P ProQ cTnI-P Phos-tag pCa50
ISHD1 Male 47 0.27 0.20 0.14 5.69
ISHD2 Male 50 0.36 0.41 0.54 5.60
ISHD3 Female 43 0.42 0.50 – –
ISHD4 Male 45 0.21 0.32 – –
ISHD5 Female 54 0.46 0.67 0.79 5.41
ISHD6 Male 55 0.67 2.20 – 5.70
ISHD7 Male 54 0.40 1.25 1.70 5.50
ISHD8 Male 54 0.31 0.33 0.44 5.73
ISHD9 Male 50 0.33 0.21 1.18 5.45
ISHD10 Male 61 0.20 0.13 0.74 5.56
IDCM1 Male 56 0.30 0.07 0 5.65
IDCM2 Male 27 0.32 0.11 0 5.65
IDCM3 Male 53 0.31 0 – 5.65
IDCM4 Male 53 0.44 0.22 0.38 5.59
IDCM5 Male 53 0.29 0.64 – –
IDCM6 Male 62 0.25 0.16 0.47 –
IDCM7 Male 53 0.18 0.38 0.46 –
IDCM8 Male 44 0.50 0.33 1.18 –
IDCM9 Female 50 0.28 0.16 0.65 5.65
IDCM10 Male 53 0.25 0.08 0.46 5.52
IDCM11 Female 52 0.18 0.17 0.51 5.68
IDCM12 Male 58 0.19 0.12 0.49 5.71
IDCM13 Female 45 0.32 0.10 – –
DONOR1 Male 39 0.62 1.96 1.75 5.65
DONOR2 Male 56 0.69 2.09 1.94 5.48
DONOR3 Male 21 0.60 4.54 1.59 5.48
DONOR4 Female 37 0.61 1.11 1.57 5.44
DONOR5 Male 23 0.64 0.94 1.74 5.52
DONOR6 Male 19 0.75 1.96 1.97 5.51
DONOR7 Female 53 0.73 1.12 1.92 –
DONOR8 Male 13 0.75 1.75 – 5.43
DONOR9 Male 65 0.49 1.09 0.98 5.63
DONOR10 Male 51 0.57 1.56 – –
Age and sex of all patients and donors with the corresponding mean value for cMyBP-C and cTnI phosphorylation determined on ProQ Diamond
stained gels (values in arbitrary units), for cTnI phosphorylation assessed by Phos-tag (in mol per mol cTnI) and for Ca2?-sensitivity of force
J Muscle Res Cell Motil (2010) 31:289–301 291
123
concentrations which were within the linear range of
detection: 20 lg for GRK2, GRK5, Gs and PP-1, and 10 lg
for Gi. Blots were pre-incubated with 0.5% milk powder in
TTBS (Tween-tris-buffered-saline: 10 mM Tris–HCl pH
7.6, 75 mM NaCl, 0.1% Tween) for 1 h at room temper-
ature. The blots were incubated overnight at 4C with
primary rabbit polyclonal antibodies (Santa Cruz) against
GRK2 (dilution 1:1000; sc-562), GRK5 (dilution 1:1000;
sc-565), Gs (Gs/olf; dilution 1:1000; sc-383), Gi (dilution
1:1000; Gi-1 sc-262, Gi-2 sc-7276, Gi-3 sc-262) or primary
mouse polyclonal antibody against PP-1 (dilution 1:50;
sc-7482, Santa Cruz). Specificity of the antibodies has been
shown in previous studies (Vinge et al. 2001; Cho and
Kehrl 2007) and all antibodies revealed one protein band in
our Western blot analysis indicative for their specificity.
Primary antibody binding was visualized using a secondary
horseradish peroxidase-labeled goat-anti-rabbit/mouse
antibody (dilution 1:2000; DakoCytomation) and enhanced
chemiluminescence (ECL plus Western blotting detection,
Amersham Biosciences). All signals were normalized to
actin (dilution 1:1000; clone KJ43A; Sigma) stained on the
same blots.
Myofilament protein phosphorylation
Myofilament protein phosphorylation was determined
using Pro-Q Diamond Phosphoprotein Stain as described
previously (Zaremba et al. 2007). To preserve the endo-
genous phosphorylation status, frozen biopsies were
homogenized in liquid nitrogen and re-suspended in 1 ml
cold 10% trichloroacetic acid solution (TCA; dissolved in
acetone containing 0.1% (w/v) dithiothreitol (DTT)). TCA-
treated tissue pellets were homogenized in sample buffer
containing 15% glycerol, 62.5 mM Tris (pH 6.8), 1% (w/v)
SDS and 2% (w/v) DTT. Tissue samples were separated on
gradient gels (Criterion tris–HCl 4–15% gel, BioRad) and
proteins were stained for one hour with Pro-Q Diamond
Phosphoprotein Stain. Fixation, washing and de-staining
were performed according to the manufacturer’s guidelines
(Molecular Probes). To assess protein content subsequently
gels were stained overnight with SYPRO Ruby stain
(Molecular Probes). Phosphorylation status of myofilament
proteins was expressed relative to protein expression of
cMyBP-C to correct for differences in sample loading.
Staining was visualized using the LAS-3000 Image Reader
and signals were analyzed with AIDA.
Cardiac troponin I phosphorylation at PKA sites Ser 23/
24 was detected with a primary rabbit polyclonal antibody
(dilution 1:500; Cell signaling) in Western blotting. In
addition, the recently developed Phos-tagTM acrylamide
(FMS Laboratory; Hiroshima University, Japan) (Kino-
shota et al. 2006) was used to visualize phosphorylated
cTnI species using alkoxide-bridged dinuclear metal
(Mn2?) complex as phosphate-binding tag (Phos-tag)
molecule. Mn2?-Phos-tag molecules preferentially capture
phosphomonoester dianions bound to Ser, Thr and Tyr
residues. Non-phosphorylated and phosphorylated cTnI
species were separated in 1D-PAGE with polyacrylamide-
bound Mn2?-Phos-tag and transferred to Western blots.
Phosphorylated cTnI species in the gel are visualized as
slower migration bands compared to the corresponding
dephosphorylated cTnI form (Kooij et al. 2010; Messer
et al. 2009).
SERCA2a and phospholamban
SERCA2a protein levels were determined immunochemi-
cally by dot-blot analysis, as described before, with minor
modifications (Muller et al. 1991). Briefly, homogenized
tissue samples (typically 0.5 lg total protein) were spotted
in triplo onto a nitrocellulose membrane. The blot was then
incubated with a 1:2500 dilution of a polyclonal antiserum
to SERCA2a and subsequently with 125I-labeled anti-
rabbit immunoglobulin G (0.05 mg/ml, specific activity
7 mCi/mg). To detect phospholamban, blots were first
incubated with a 1:2500 dilution of a monoclonal anti
mouse antibody (Affinity Bioreagents) and subsequently
with 125I-labeled anti-mouse immunoglobulin G. Blots
were exposed to Phosphor Imager screens, which were then
scanned and spots were quantified using ImageQuant
software (Molecular Dynamics). All protein values for
ISHD and IDCM samples were normalized to the average
value observed in donor, which was set to 1.
Force measurements in single cardiomyocytes
Force measurements were performed in single, mechani-
cally isolated cardiomyocytes as described previously
(Kooij et al. 2010; van der Velden et al. 2003). Tissue
samples were defrosted in relaxing solution (in mmol/l:
free Mg, 1; KCl, 145; EGTA, 2; MgATP, 4; imidazole, 10;
pH 7.0), mechanically disrupted and incubated for 5 min in
relaxing solution supplemented with 0.5% Triton X-100 to
remove all membrane structures. Subsequently, cells were
washed twice in relaxing solution, after which single
cardiomyocytes were attached with silicone adhesive
between a force transducer and a motor. Sarcomere length
of isolated cardiomyocytes was adjusted to 2.2 lm. The
pCa (-10log[Ca
2?]) ranged from 9.0 (relaxation solution)
to 4.5 (maximal activation). All force values were nor-
malized for cardiomyocyte cross-sectional area. Exposure
to a series of solutions with intermediate pCa values (pCa
6.0–5.0) yielded the baseline force-pCa relation. On
transfer of the cardiomyocyte from relaxing to activating
solution, isometric force started to develop. Once a steady
state force level was reached, the cell was shortened within
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1 ms to 80% of its original length to determine the baseline
of the force transducer. The distance between the baseline
and the steady force level is the total force (Ftotal). After
20 ms, the cell was restretched and returned to the relaxing
solution, in which a second slack test, of 10 s duration was
performed to determine passive force (Fpassive). Active
force was obtained by subtracting passive force from the
total force, i.e., Factive = Ftotal - Fpassive.
Quantitative histomorphometry
Histomorphologic analysis of tissues was performed on
elastica-von-Giesson and hematoxylin-eosin-stained 4 lm
thick sections of tissue fixed in 5% formalin (Borbe´ly et al.
2005). Images of these sections were acquired using a
projection microscope (950). Subsequent image analysis,
using SlidebookTM 4.0 software (3I, Denver, Co), was
performed to determine cardiomyocyte diameter and the
extent of interstitial fibrosis, which was expressed as col-
lagen volume fraction. Areas of reparative and perivascular
fibrosis were excluded. Cardiomyocyte diameter was
determined perpendicularly to the outer contour of the cell
membrane at nucleus level in 15 representative myocytes
of the cardiac tissue section, and collagen volume fraction
was calculated as the sum of all connective tissue areas
divided by the sum of all connective tissue and muscle
areas averaged over 4–6 representative fields of the cardiac
tissue section. Data were averaged per heart sample and
averaged to obtain the mean of the group. For analysis of
cardiomyocyte diameter and collagen volume fraction 9
ISHD, 7 IDCM and 5 donor hearts were included.
Analysis of myofibrillar density was performed in 8
ISHD, 6 IDCM and 5 donor hearts. Tissues samples were
fixed in 2% (v/v) gluteraldehyde for 30 min and 1.5% (w/v)
osmium tetroxide for 10 min dehydrated with acetone and
embedded in Epon812. Ultrathin sections were collected on
300-mesh Formavar-coated Nickel-grids. The sections were
contrasted with uranyl acetate and lead citrate and were
examined in a Jeol-1200EX electron microscope. Quanti-
tative analysis was performed with the above mentioned
automated image analyzer. Cardiomyocyte myofibrillar
density was calculated from the sum of the myofibrillar
areas related to total cellular area in 4–6 representative
myocytes per sample. Data were averaged per heart.
Data analysis
Competition binding data were analyzed by fitting mono-
and biphasic sigmoidal functions to the experimental data;
a biphasic fit was accepted only if it resulted in a significant
improvement as judged by an F-test. Resulting IC50 values
for the high and low affinity component of inhibition were
converted to Ki values based upon the Cheng–Prusoff
equation (Cheng and Prusoff 1973) and assuming a Kd
value of ICYP of 72 pM (n = 4). Due to limited tissue
availability, receptor density (Bmax) was estimated based
upon the specific binding (SB) of the single radioligand
concentration (L) in the competition experiments relative
to its Kd using the equation Bmax = SB/(1 - 1/(L/
Kd ? 1)). The statistical significance of inter-group dif-
ferences was assessed by one-way ANOVA followed by
Dunnett’s post-hoc tests.
Values are given as mean ± SEM of n observations.
The mean data values of protein and histological analysis
and force measurements in ISHD, IDCM and donor sam-
ples were compared using one-way ANOVA and Bonfer-
roni-post tests. P \ 0.05 was considered significant. All
statistical analysis was performed with Prism (version 4.01,
Graphpad Software, San Diego, CA, USA).
Results
Components of the b-adrenergic receptor pathway
In all cases except one competition by the highly
b1-selective antagonist CGP 20712A resulted in biphasic
curves (Fig. 1a). The -log Ki values for high and low
affinity sites, which identify b1AR and b2AR, respectively,
were not significantly different between IDCM (8 hearts;
8.21 ± 0.19 and 5.59 ± 0.09) and ISHD (8 hearts;
8.17 ± 0.09 and 5.62 ± 0.10) myocardium, and did not
differ from the values observed in donor (7 hearts;
8.55 ± 0.12 and 5.74 ± 0.11). Single point estimates of
total bAR density, revealed significantly reduced bAR
density in IDCM compared to donor, while the value
observed in ISHD was intermediate between IDCM and
donor (Fig. 1b). The percentage of b1ARs did not differ
between IDCM (50 ± 4%) and ISHD (47 ± 9%) samples
and was comparable to the value observed in donor
(52 ± 6%).
No difference was found in expression of GRK2
between IDCM and ISHD, while GRK5 was significantly
higher in ISHD than in IDCM myocardium (Table 2).
Compared to donor GRK2 was significantly lower in both
failing groups, while GRK5 was significantly higher in the
ISHD group. Gs expression did not differ between ISHD
and IDCM, though was significantly lower in both failing
groups compared to donor (Fig. 1c; Table 2). In addition to
Gs, we have analyzed three isoforms of inhibitory G-pro-
tein: Gia-1, Gia-2 and Gia-3. The heterotrimeric G-proteins
are composed of a, b and c subunits, of which the a-subunit
confers specificity to the G-protein (Wang and Dhalla
2000). Gia-1 expression was significantly higher in IDCM
than in ISHD and donor (Fig. 1d), while Gia-2 was signif-
icantly higher in both failing groups compared to donor
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(Table 2).The Gia-3 expression level was not altered in
patient groups (data are summarized in Table 2).
Myofilament and calcium handling proteins
ProQ Diamond phosphostaining was used to detect phos-
phorylation of myofilament proteins. Figure 2a shows
ProQ Diamond-stained cardiac samples from ISHD, donor
(D) and IDCM myocardium separated on a gradient gel.
The same gel was subsequently stained with SYPRO Ruby
for analysis of total protein content (Fig. 2b). The ProQ
Diamond stained gel shows lower endogenous phosphor-
ylation of the PKA-target proteins cMyBP-C and cTnI in
failing compared to -donor. Noteworthy, cTnI phosphory-
lation was significantly higher in ISHD compared to IDCM
(Fig. 2c). In addition, phosphorylation of cMyBP-C was
higher in ISHD compared to IDCM, though not signifi-
cantly (P = 0.07). When the failing and donor were
combined, a monovariate linear regression analysis
revealed significant correlations between the ProQ Dia-
mond-assessed phosphorylation status of cMyBPC and
cTnI (P \ 0.0001; R2 = 0.75) (Fig. 2d).
Higher PKA-mediated phosphorylation of cTnI (at
Ser23 and Ser24, i.e., PKA sites) in ISHD compared to
IDCM was confirmed in Western blotting (Fig. 3). Con-
sistent with ProQ Diamond analysis of cTnI phosphoryla-
tion, the Western blots revealed significantly lower cTnI
phosphorylation at PKA-sites in failing compared to donor.
Analysis of cTnI species separated by Phos-tag poly-
acrylamide gels revealed three bands upon staining of
Western blots with a specific anti-cTnI antibody (8I-7) in
donor, while only two bands were observed in the failing
sample shown in Fig. 4a. The lower band was recognized
by an antibody directed against cTnI unphosphorylated at
PKA sites (22B11). The upper band was recognized by the
phosphorylation-specific antibody which recognizes the
PKA-sites Ser 23 and Ser 24. The second band on the blot
is the mono-phosphorylated form of cTnI (Messer et al.
2009). Phos-tag analysis of samples from all groups are
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Table 2 Protein analysis
ISHD
(n = 9)
IDCM
(n = 13)
Donor
(n = 8)
GRK2 (a.u.) 0.72 ± 0.07# 0.62 ± 0.13# 1.00 ± 0.07
GRK5 (a.u.) 1.92 ± 0.23# 1.33 ± 0.19* 1.00 ± 0.20
Gs (a.u.) 0.39 ± 0.10# 0.45 ± 0.13# 1.00 ± 0.30
Gia-1 (a.u.) 1.00 ± 0.20 3.36 ± 0.91#,* 1.00 ± 0.30
Gia-2 (a.u.) 2.17 ± 0.40# 3.18 ± 0.80# 1.00 ± 0.10
Gia-3 (a.u.) 0.81 ± 0.18 1.19 ± 0.30 1.00 ± 0.30
MLC-2P (a.u.) 1.60 ± 0.22# 0.89 ± 0.16* 1.00 ± 0.07
PP-1 (a.u.) 1.51 ± 0.19 2.45 ± 0.35#,* 1.00 ± 0.40
Phospholamban
(a.u.)
1.43 ± 0.14# 1.55 ± 0.08# 1.00 ± 0.04
SERCA2a (a.u.) 0.99 ± 0.07 0.72 ± 0.06#,* 1.00 ± 0.07
All signals in IDCM and ISHD samples were normalized to the
averaged value observed in donor, which was set to 1. GRK G-cou-
pled receptor kinase, Gs G-stimulatory, Gi G-inhibitory, MLC-2P
phosphorylated myosin light chain 2, PP-1 protein phosphatase 1. a.u.
arbitrary units, n number of heart samples. * P \ 0.05 in Bonferroni-
post tests, IDCM versus ISHD; # P \ 0.05, in Bonferroni-post tests,
failing versus donor
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shown in Fig. 4b. The distribution of the cTnI forms was
significantly different among the three groups (Fig. 4c).
The unphosphorylated form was highest in IDCM, while
the bisphosphorylated form was highest in donor. A sig-
nificant correlation was observed between phosphorylated
cTnI on Phos-tag and cTnI phosphorylation analyzed by
ProQ Diamond (Fig. 4d; P \ 0.0001; R2 = 0.75).
ProQ Diamond analysis also revealed higher phospho-
rylation of myosin light chain 2 (MLC-2) in ISHD com-
pared to both IDCM and donor (Table 2), while there were
no significant differences in phosphorylation of the other
myofilament proteins, desmin and troponin T (data not
shown). The difference in MLC-2 phosphorylation may be
in part explained by differences in PP-1 expression. Wes-
tern blot analysis of PP-1 revealed significantly higher PP-1
expression in IDCM compared to ISHD and donor
(Table 2).
Western blot analysis showed increased phospholamban
protein levels in IDCM and ISHD compared to donor and a
significantly lower SERCA2a level in IDCM compared to
both ISHD and donor (Table 2). The ratio of phospho-
lamban over SERCA2a significantly differed among
groups and was highest in IDCM.
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Fig. 2 a ProQ Diamond-
stained and b SYPRO-stained
gel of ISHD, donor (D) and
IDCM samples. The ProQ
Diamond stained gel clearly
shows higher phosphorylation
of cardiac cMyBP-C and cTnI
in donor compared to the ISHD
and IDCM sample. c The mean
values are shown in the bar
graph. Phosphorylation of cTnI
was significantly higher in
ISHD compared to IDCM. d A
significant positive correlation
was found between the
phosphorylation status of
cMyBP-C and cTnI
(P \ 0.0001; R2 = 0.75). MHC
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Fig. 3 Western blot analysis of troponin I (cTnI) phosphorylation at
the PKA-sites Ser 23/24 revealed significantly higher cTnI phosphor-
ylation in ISHD compared to IDCM, while cTnI phosphorylation was
lower in both failing groups compared to donor. *P \ 0.05 in
Bonferroni-post tests, IDCM versus ISHD; #P \ 0.05, in Bonferroni-
post tests, failing versus donor
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Higher Ca2?-sensitivity in IDCM than in ISHD
Force measurements were performed in single cardio-
myocytes isolated from 8 IDCM hearts (42 cardiomyo-
cytes), 8 ISHD hearts (27 cardiomyocytes) and 8 donor
hearts (41 cardiomyocytes). Cross-sectional area of the
cardiomyocytes determined at a sarcomere length of
2.2 lm was significantly higher in IDCM (556 ± 44 lm2)
and ISHD (690 ± 75 lm2) compared to donor (339 ±
26 lm2) (P \ 0.05 in one-way ANOVA).
Maximal active tension (Factive) did not differ (Fig. 5a),
while passive tension (Fpassive) was significantly lower
in IDCM and ISHD compared to donor (Fig. 5b).
Noteworthy, myofilament pCa50 was significantly lower in
ISHD compared to IDCM (Fig. 5c, d). A significantly
higher pCa50 was found in failing heart compared to donor
(Fig. 5c, d). Moreover, the steepness of the sigmoidal
force-pCa relationship (nHill) was significantly higher in
ISHD (4.05 ± 0.12) compared to IDCM (3.58 ± 0.10) and
donor (3.70 ± 0.14). A monovariate linear regression
analysis revealed a significant correlation between pCa50
and phosphorylated cMyBP-C (P \ 0.05; R2 = 0.24)
(Fig. 5e), while no significant correlation was found
between pCa50 and ProQ Diamond-analyzed phospho-
rylated cTnI (P = 0.09; R2 = 0.12). Troponin I phospho-
rylation determined by Phos-tag analysis did significantly
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troponin I (cTnI) species
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phosphorylated cTnI (22B11),
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cTnI phosphorylation at PKA
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correlate with pCa50 (P \ 0.01; R
2 = 0.43) (Fig. 5f). The
individual data per patient/donor for phosphorylation of the
PKA target proteins, cMyBP-C and cTnI, and myofilament
Ca2?-sensitivity are summarized in Table 1.
Structural alterations
Representative examples of light microscopy and electron
microscopy images of LV sections from the three groups
are shown in Fig. 6a and b, respectively. Cardiomyocyte
diameter did not differ between ISHD and IDCM, but was
significantly higher than observed in donor (Fig. 6c).
Collagen volume fraction was significantly higher in IDCM
compared to ISHD. Moreover, collagen volume fraction
was significantly higher in both failing compared to donor
(Fig. 6d). No differences were found in myofibrillar den-
sity between ISHD and IDCM, while it was significantly
lower in both failing compared to donor (Fig. 6e).
Discussion
In the present study, diverse changes were found in the
bAR pathway in IDCM and ISHD patients. The results
indicate that there are differences in the cellular structure
and function between both patient groups. Compared to
ISHD, IDCM was characterized by a more severe receptor
bAR down-regulation and increased Gi expression,
increased PP-1 expression, an enhanced reduction in
protein phosphorylation, increased myofilament pCa50,
reduced SERCA2a expression and higher collagen volume
fraction. The data indicate that cellular dysfunction is more
severe in IDCM than in ISHD patients.
Changes in components of the b-adrenergic pathway
In the present study, total bAR density was significantly
reduced in IDCM compared to donor with intermediate
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Fig. 5 a Factive did not differ
among groups. b Fpassive was
significantly lower in failing
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d pCa50 was significantly higher
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donor. The pCa50 was
significantly lower in ISHD
compared to IDCM. e A
significant correlation was
observed between pCa50 and
phosphorylated cMyBP-C
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phosphorylation (P \ 0.01;
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Bonferroni-post tests, IDCM
versus ISHD; #P \ 0.05, in
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values in ISHD. This down-regulation may have been
caused by reduced mRNA levels (Hadcock and Malbon
1998). In addition, bAR may be degraded upon internali-
zation of receptors, which is preceded by the process of
receptor uncoupling (Wang and Dhalla 2000). The regu-
lating step in the latter process is receptor phosphorylation,
either by second-messenger activated kinases such as PKA,
or by GRKs, which only phosphorylate agonist occupied
receptors (Fig. 7). Both GRK2 and GRK5 are determinants
of bAR responsiveness of the heart, as they disrupt the
interaction between receptors and the heterotrimeric G
proteins (Wang and Dhalla 2000). This process of receptor
uncoupling is thought to be an important contributor to
bAR desensitization and down-regulation due to increased
sympathetic tone in cardiac disease. In failing human tis-
sue, Ungerer et al. (1993, 1994) showed increased GRK2
mRNA and activity in both ISHD and IDCM. In contrast,
in the present study we observed lower GRK2 protein
expression in both failing groups compared to donor, while
GRK5 protein expression was significantly higher in ISHD
compared to IDCM and donor.
The discrepant observation in GRK5 between ISHD and
IDCM may reflect a difference in severity of disease, as
Leineweber et al. (2005) observed an increase in GRK
activity in right atrial tissue from patients at NYHA I and
II, while in more severe stages (NYHA III and IV) GRK
activity was similar as observed in controls. Interestingly,
bAR density did not differ in NYHA I and II and was
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Fig. 6 Light microscopy (a) (hematoxylin-eosin stained; scale
10 lm) and electron microscopy (b; 36009 magnification) images
of left ventricular sections from the three groups. Bar graphs showing
cardiomyocyte diameter (c), collagen volume fraction (d) and
myofibrillar density (e). A significant increase was observed in
cardiomyocyte diameter and collagen volume fraction in both failing
groups compared to donor. Analysis of cardiomyocyte diameter and
collagen volume fraction were performed in 9 ISHD, 8 IDCM and 5
donor hearts. In addition, a significantly lower myofibrillar density
was present in failing groups compared to donor. Analysis of
myofibrillar density was performed in 8 ISHD, 6 IDCM and 5 donor
hearts. The collagen volume fraction in IDCM was significantly
higher compared to ISHD. *P \ 0.05 in Bonferroni-post tests, IDCM
versus ISHD; #P \ 0.05, in Bonferroni-post tests, failing versus
donor. Arrow to indicate collagen
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significantly reduced compared to controls in NYHA III
and IV. These data are suggestive for a transient increase in
GRK activity during the course of heart failure, and indi-
cate that increases in GRK precede receptor down-regula-
tion in the human heart. Accordingly, the high GRK5
expression and the lower reduction in bAR density in ISHD
compared to IDCM observed in the present study may
reflect a less severe disease stage in ISHD, despite similar
NYHA classification. The latter is further supported by the
significantly higher expression of inhibitor G-protein in
IDCM compared to ISHD.
More severe cellular phenotype in IDCM compared
to ISHD
Analysis of sarcomeric protein phosphorylation revealed
significant differences in the bAR target proteins cMyBP-C
and cTnI. Consistent with previous studies (El-Armouche
et al. 2007; van der Velden et al. 2003; Messer et al. 2007,
2009; Copeland et al. 2010) phosphorylation of cMyBP-C
and cTnI was significantly lower in both failing groups
compared to donor, which has been explained by reduced
PKA-mediated phosphorylation due to bAR desensitization
and down-regulation in cardiac disease (Wolff et al. 1996;
van der Velden et al. 2003). Noteworthy, cMyBP-C and
cTnI phosphorylation was lower in IDCM compared to
ISHD, which fits the larger reduction in bAR density and
larger increase in Gai-1 expression observed in IDCM
compared to ISHD. The higher myofilament pCa50 in
IDCM compared to ISHD may be well explained by the
significantly lower (PKA-mediated) myofilament protein
phosphorylation observed in IDCM.
Interestingly, analysis of cTnI species using Phos-tag
polyacrylamide gels showed that the difference in cTnI
phosphorylation between IDCM and donor can be largely
explained by a difference in the bis-phosphorylated form of
cTnI (Fig. 4c). It is tempting to speculate that a difference
in cTnI phosphorylation at PKA sites Ser 23/24 underlies
the differences in pCa50 among groups. Although a sig-
nificant correlation was found between myofilament pCa50
and phosphorylation status of cMyBP-C (Fig. 5e), the
correlation with ProQ Diamond assessed cTnI phosphory-
lation did not reach statistical significance (P = 0.09).
Noteworthy, cTnI phosphorylation determined with the
Phos-tag assay did significantly correlate with myofila-
ment Ca2?-sensitivity (Fig. 5f), indicating that Phos-tag
analysis is a very accurate method to determine cTnI
phosphorylation.
The correlation between cMyBP-C phosphorylation and
pCa50 was stronger when cMyBP-C phosphorylation was
combined with ProQ-Diamond assessed cTnI phosphory-
lation (P = \0.05; R2 = 0.27; not shown). In a recent
study in human myocardium we showed that myofibrillar
targets of PKA, cMyBP-C and/or titin, play an important
role in modulating the effect of cTnI phosphorylation on
pCa50 in human myocardium (Kooij et al. 2010). Exchange
of endogenous (mostly unphosphorylated) cTnI with PKA-
phosphorylated troponin complex did not reduce pCa50 in
failing cardiomyocytes, in which endogenous cMyBP-C
phosphorylation is low. Accordingly, our present data are
compatible with a modulatory role for cMyBP-C in force
development at submaximal calcium concentrations in
human myocardium.
In addition to the PKA targets, cTnI and cMyBP-C,
phosphorylation of MLC-2 was significantly lower in
IDCM than in ISHD. Dephosphorylation of MLC-2 occurs
via PP-1, which was significantly higher in IDCM com-
pared to ISHD. Although increased PP-1 expression may
explain the relatively low MLC-2 phosphorylation in
IDCM, it cannot explain the significantly lower MLC-2
phosphorylation in donor compared to ISHD, as PP-1
expression tended to be even lower in donor compared to
ISHD. Other kinases/phosphatases most likely underlie the
differences in MLC-2 phosphorylation observed between
ISHD and donor myocardium and warrant future research.
Moreover, upon activation of bAR, PP-1 activity is
depressed by PKA via phosphorylation of protein inhibi-
tor 1 (I1) (Neumann et al. 1991). Thus, apart from
increased PP-1 expression, perturbations in bAR signaling
will increase activity of PP-1, which may explain the
lower MLC-2 phosphorylation in IDCM compared to
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MLC2-P
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Fig. 7 Activation of b-adrenergic receptor pathway in the heart.
Overall, changes were more severe in IDCM compared to ISHD,
indicated by the dotted arrows, i.e., decrease or increase in IDCM
compared to ISHD. P Phosphorylation, bAR b-adrenergic receptor,
Gs G-stimulatory protein, Gi G-inhibitory protein, GRK G-coupled
receptor kinase, Ca2? calcium, ATP adenosine tri-phosphate, cAMP
cyclic AMP, PKA Protein kinase A, PP-1 protein phosphatase 1,
MLC-2 myosin light chain 2, cMyBP-C cardiac myosin binding
protein C, cTnI cardiac troponin I, SERCA2a SR Ca2?ATPase
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ISHD. Increased activity and mRNA level of PP-1 has
been reported previously in human IDCM (Neumann
et al. 1997). Increased activity of PP-1 in a transgenic
mouse model resulted in decreased myocardial contrac-
tility and dilated cardiomyopathy underscoring a detri-
mental role for PP-1 in heart failure (Carr et al. 2002).
Increased PP-1 will also impair Ca2?-handling by
dephosphorylation of phospholamban. The resulting
reduction in SR Ca2? loading will be enhanced further by
the reduction in SERCA2a expression in IDCM. Although
several studies did not find differences in SERCA2a and
PLB at mRNA levels between ISHD and IDCM (Arai
et al. 1993; Flesch et al. 1996), our study showed reduced
SERCA2a protein expression in IDCM, and increased
phospholamban expression in both failing groups. Higher
PP-1 expression and lower SERCA2a expression are
indicative for a more severe cellular phenotype in patients
with IDCM.
In line with previous studies (Anversa et al. 1986;
Parodi et al. 1993; Weber 1989) we observed three struc-
tural alterations in end-stage heart failure: increased car-
diomyocyte diameter (Fig. 6c), increased collagen volume
fraction (Fig. 6d) and decreased myofibrillar density
(Fig. 6e). While no difference was found in cardiomyocyte
diameter and myofibrillar density between IDCM and
ISHD, collagen volume fraction was significantly higher in
IDCM compared to ISHD, which is in line with a previous
study by Parodi et al. (1993).
Adaptive cellular mechanism
In agreement with previous studies (Makarenko et al.
2004; Nagueh et al. 2004; Neagoe et al. 2002) Fpassive in
end-stage human heart failure was lower in comparison to
donor. It has been proposed that the reduction in Fpassive is
due to a shift in titin isoform composition, from the stiff
N2B to the more compliant N2BA isoform (Makarenko
et al. 2004; Nagueh et al. 2004). In contrast, enhanced
Fpassive was found in patients with less severe forms of
heart failure (NYHA II-III) (Borbe´ly et al. 2005, 2009;
van Heerebeek et al. 2006), in which a similar shift in
titin isoform composition was found as observed in end-
stage heart failure (i.e., more compliant isoform). The
increased Fpassive at an early phase of heart failure was
related with relative hypophosphorylation of the stiff N2B
titin isoform (Borbe´ly et al. 2009). Cardiomyocyte stiff-
ness reflects the balance between isoform composition
and isoform-specific phosphorylation status of titin. The
shift to the compliant N2BA isoform during heart failure
seems to be an adaptive mechanism to lower passive
force (Makarenko et al. 2004), which may be maximal at
end-stage heart failure.
Conclusions
Comparison of myocardium from patients with ISHD and
IDCM end-stage HF revealed more severe cellular pertur-
bations in patients with IDCM which are summarized in
Fig. 7. Our data support previous studies in which transient
changes were observed in the bAR pathway. Increased
GRK expression may be a primary event and possibly
precedes the reduction in bAR density, and the changes in
expression of proteins involved in calcium handling and
PP1. Noteworthy, Leineweber et al. (2005) showed that
GRK5 was significantly lower in patients treated with
b-blockers only in the relatively early stages of heart fail-
ure (i.e., NYHA I and II), in which GRK5 was higher
compared to the end-stage of HF. Hence, the response to
current treatment may depend on cause of cardiac disease,
and may be less in patients with IDCM.
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